IONSSTOCK_USDT
幣種名稱 IONSSTOCK
流通率 0.00%
交易規則 (IONSUSDT Perpetual)
槓桿倍數 1 ~ 20
最小下單數量 0.5285 USDT
市價單單筆最大下單數量 5,417.125 USDT
限價單單筆最大下單數量 5,417.125 USDT
最小變動價位 0.01
限價訂單價格上限/下限比例 20% / 20%
最大掛單數量 50
價差保護閾值 10%
合約面值 1 張 = 0.01 IONS
強平手續費率 0.02%
查看所有合約交易規則基於各類指標等數據計算得到的分析，用於輔助判斷買入和賣出訊號。
數值指標
| 名稱 | 數值 | 操作 |
|---|
| KDJ (9,3,3)_K | 40.3403 | 買入 |
| KDJ (9,3,3)_D | 45.4363 | 中立 |
| KDJ (9,3,3)_J | 30.1483 | 買入 |
| RSI (14) | 100 | 賣出 |
| StochRSI (%K) | 0 | 買入 |
| StochRSI (%D) | 0 | 買入 |
多維度指標
| 名稱 | 操作 |
|---|
| KDJ (9,3,3)_K&D | 中立 |
| KDJ (9,3,3) 金叉死叉 | 賣出 |
| MACD (12,26,9) 金叉死叉 | 中立 |
| DEA 穿過零軸 | 中立 |
| BOLL (20,2) 超買超賣 | 中立 |
| BOLL (20,2) 中軌金叉死叉 | 中立 |
總結: 賣出 4 · 中立 6 · 買入 16 — 買入
簡介
Ionis Pharmaceuticals, Inc. is an industry leader in the invention and development of antisense drugs, utilizing its new drug development platform to develop a large number of best-in-class medicines. Antisense technology opens a bridge between genetics and pharmaceuticals. With its highly efficient and prolific drug development platform, the company can expand its own and its partners' drug portfolios with antisense drugs, meeting a wide range of pharmaceutical needs. The company's strategy is to do what it does best—find unique antisense drugs and develop them into key clinical inflection points. The company invents and conducts early-stage research on new drugs, then licenses them to partners. The company maximizes the value of its drugs by outsourcing late-stage development to leading pharmaceutical companies such as Biogen Idec, Bristol-Myers Squibb, Genzyme, Sanofi, GlaxoSmithKline, and Eli Lilly. Ionis Pharmaceuticals, Inc.'s flagship product, KYNAMRO, is targeting patients with familial hypercholesterolemia. The company was founded in California, USA in 1989.
Disclaimer: Data is collected from third-party platforms, provided for reference only, and does not constitute any form of investment advice or guarantee.
